24
Participants
Start Date
March 25, 2019
Primary Completion Date
July 20, 2019
Study Completion Date
July 20, 2019
Placebo
For each dose group a placebo group was given matching placebo tablets, participants were randomized within each dose group in a 3:1 ratio (active drug:placebo), tablets taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
Dose group 1 - 50 mg BI 1358894
2 film-coated tablets of 25 milligram (mg) BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
Dose group 2 - 100 mg BI 1358894
1 film-coated tablet of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
Dose group 3 - 200 mg BI 1358894
2 film-coated tablets of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY